Raphael Erez reported grant involving 297,000 shares of DarioHealth Corp. at $0.00 for $0 on Sep 24, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Executive Officer
Chief Executive Officer
Filed Sep 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
297,000Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
454,432Direct
Trade date
Sep 24, 2026Grant
Filed
Sep 28, 2026, 4:05 PM ET4-day reporting delay
Accession
0001104659-26-111343Code A · Transaction 230301
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 12, 2024Conversion579$19.10$11,058.90Trade 230300
Aug 12, 2024Conversion30$1,000.00−$30,000Trade 230302
3 transaction rows in this filing. Joint filers share the same rows.

DRIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
DRIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 5, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. F2: The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion. F3: The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period.